Evolution of the Average Target: Charles River Laboratories International, Inc.

Evolution of the Average Target - Charles River Laboratories International, Inc.

Evolution of the Target Price: Charles River Laboratories International, Inc.

Evolution of the Target Price - Charles River Laboratories International, Inc.

Changes in Analyst Recommendations: Charles River Laboratories International, Inc.

547ab91ec7a0.i0j2NNgn8qMcx6g9Zm5f38aJ5I7sMOtS7w6Ns_9yv4U.wAOeQ5dJlPVon85aPCsXqoPQpaOCfIg4tzbD2LYn_s64DqlirnSU-2bqyw~621836e872b5c945e6e1fcf93e3247f2
09:11am Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $340 From $300 MT
Sep. 30 UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175 MT
Sep. 28 Jefferies Adjusts PT on Charles River Laboratories International to $340 From $305, Maintains Buy Rating MT
Sep. 25 Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says MT
Sep. 25 Deutsche Bank Raises Price Target on Charles River Laboratories International to $320 From $300, Keeps Buy Rating MT
Sep. 25 RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating MT
Sep. 25 Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating MT
Sep. 25 Mizuho Adjusts PT on Charles River Laboratories International to $295 From $264, Keeps Neutral Rating MT
Sep. 25 Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating MT
Sep. 25 TD Cowen Adjusts PT on Charles River Laboratories International to $325 From $300, Maintains Buy Rating MT
Sep. 25 Baird Adjusts PT on Charles River Laboratories International to $334 From $291, Keeps Outperform Rating MT
Sep. 17 Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating MT
Sep. 11 Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating MT
Aug. 10 TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating MT
Aug. 10 Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating MT
Aug. 06 Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220 MT
Aug. 06 RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating MT
Aug. 06 Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating MT
Aug. 06 Analyst recommendations: AppLovin, Emerson Electric, Roblox, Flutter Entertainment, HubSpot... Zonebourse
Aug. 06 JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180 MT
Jul. 20 Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… Zonebourse
Jul. 13 BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 MT
Jul. 13 Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating MT
Jul. 13 Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating MT
Jul. 09 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+20.88%
+39.25%
+20.5%
+13.53%
+36.56%
+22.87%
+49.08%
+10.4%
+19.76%
Average +25.87%
Weighted average by Cap. +25.83%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
301.79USD
Average target price
310.53USD
Spread / Average Target
+2.90%
High Price Target
357.00USD
Spread / Highest target
+18.29%
Low Price Target
145.00USD
Spread / Lowest Target
-51.95%

Analyst Consensus Detail

Analyst consensus - Charles River Laboratories International, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Charles River Laboratories International, Inc.
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Charles River Laboratories International, Inc.
  1. Stock Market
  2. Stocks
  3. CRL Stock
  4. CRL Stock
  5. Consensus Charles River Laboratories International, Inc.